Abbott Issues FY23 Earnings, Sales Growth View - Update

(RTTNews) - Abbott Laboratories (ABT), while announcing weak fourth-quarter results, issued fiscal 2023 earnings and sales forecast.

For the year, the company projects earnings per share from continuing operations of $3.05 to $3.25 and adjusted earnings per share from continuing operations of $4.30 to $4.50.

On average, 21 analysts polled by Thomson Reuters expect earnings of $4.4 per share for the year. Analysts' estimates typically exclude special items.

Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID-19 testing-related sales of around $2.0 billion.